Related Experiment Video

Updated: Dec 3, 2025

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation
07:46

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation

Published on: October 25, 2024

3.9K

Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy

Tewodros Shibabaw1

  • 1Department of Biochemistry, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

Journal of Inflammation Research
|October 29, 2020
PubMed

Insights

Effective pharmacotherapy is crucial for managing Coronavirus disease 2019 (COVID-19). Targeting interleukin-17A (IL-17A) and interleukin-6 (IL-6) may help manage severe COVID-19, especially in cytokine storm syndrome.

Area of Science:

  • Immunology
  • Virology
  • Pharmacology

Background:

  • Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, presents a global health challenge.
  • Severe COVID-19 cases often involve hypercytokinemia and cytokine release syndrome.
  • Elevated pro-inflammatory cytokines, including IL-17, are implicated in COVID-19 immunopathology and acute respiratory distress syndrome.

Purpose of the Study:

  • To review the mechanism of T-helper 17 cell polarization in SARS-CoV-2 infection.
  • To explore the role of IL-17A and IL-6 in COVID-19 pathogenesis.
  • To propose therapeutic strategies targeting IL-17A and IL-6 for COVID-19 management.

Main Methods:

  • Literature review focusing on T-cell polarization and cytokine signaling in COVID-19.
  • Analysis of the immunopathological mechanisms driven by SARS-CoV-2 infection.
  • Review of existing data on cytokine targeting therapies.

Main Results:

  • SARS-CoV-2 infection promotes the polarization of naive CD4+ T cells towards Th17 cells.
  • IL-17A and IL-6 play significant roles in the cytokine storm and immunopathology of severe COVID-19.
  • Targeting IL-17A and IL-6 pathways shows potential for managing COVID-19 patients.

Conclusions:

  • Understanding Th17 cell polarization is key to comprehending COVID-19 immunopathology.
  • IL-17A and IL-6 are critical therapeutic targets for severe COVID-19.
  • Targeting IL-17A and IL-6 offers a promising pharmacotherapy strategy for COVID-19 patients, particularly those with cytokine storm syndrome.
Keywords:
ARDSCOVID-19IL-17AIL-6Th17cytokine stormimmunopathologyinflammation

More Related Videos

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

2.2K
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

35.2K

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.8K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.8K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
867
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
329
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
349